Close Menu
    Facebook X (Twitter) Instagram
    • Home
    • About Us
    • Digital Subscription
    • Advertisement
    • Contact Us
    Facebook X (Twitter) Instagram
    The Tennessee TribuneThe Tennessee Tribune
    Advertise With Us
    • Home
      • COVID-19 Resource Center
        • Dr. Henry Louis Gates’ PSA Radio
      • Featured
    • News
      • State
      • Local
      • National/International News
      • Global
      • Business
        • Commentary
        • Finance
        • Local Business
      • Investigative Stories
        • Affordable Housing
        • DCS Investigation
        • Gentrification
    • Editorial
      • National Politics
      • Local News
      • Local Editorial
      • Political Editorial
      • Editorial Cartoons
      • Cycle of Shame
    • Community
      • History
      • Tennessee
        • Chattanooga
        • Clarksville
        • Knoxville
        • Memphis
      • Public Notices
      • Women
        • Let’s Talk with Ms. June
    • Education
      • College
        • American Baptist College
        • Belmont University
        • Fisk
        • HBCU
        • Meharry
        • MTSU
        • University of Tennessee
        • TSU
        • Vanderbilt
      • Elementary
      • High School
    • Lifestyle
      • Art
      • Auto
      • Tribune Travel
      • Entertainment
        • 5 Questions With
        • Books
        • Events
        • Film Review
        • Local Entertainment
      • Family
      • Food
        • Drinks
      • Health & Wellness
      • Home & Garden
      • Featured Books
    • Religion
      • National Religion
      • Local Religion
      • Obituaries
        • National Obituaries
        • Local Obituaries
      • Faith Commentary
    • Sports
      • MLB
        • Sounds
      • NBA
      • NCAA
      • NFL
        • Predators
        • Titans
      • NHL
      • Other Sports
      • Golf
      • Professional Sports
      • Sports Commentary
      • Metro Sports
    • Media
      • Video
      • Photo Galleries
      • Take 10
      • Trending With The Tribune
    • Classified
    • Obituaries
      • Local Obituaries
      • National Obituaries
    The Tennessee TribuneThe Tennessee Tribune
    Bypass

    Pfizer, BioNTech Expecting Phase III Trial Results For Booster Dose

    zenger.newsBy zenger.newsAugust 18, 2021No Comments4 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    NEW YORK — Pfizer and BioNTech are making a strong case for the authorization of a third or booster dose of the companies’ Covid-19, for which they have submitted the phase I data of clinical trials evaluating the safety and immunogenicity of the dose.

    The data will also be submitted to the European Medicines Agency and other regulatory authorities in the coming weeks, Pfizer said in a statement released on Aug. 16.

    “Vaccination is our most effective means of preventing Covid-19 infection—especially severe disease and hospitalization—and its profound impact on protecting lives is indisputable,” Albert Bourla, chairman and chief executive officer, Pfizer, said in the statement. 

    “Still, with the continuing threat of the Delta variant and possible emergence of other variants in the future, we must remain vigilant against this highly contagious virus.”

    “The data we’ve seen to date suggests the third dose of our vaccine elicits antibody levels that significantly exceed those seen after the two-dose primary schedule. We are pleased to submit these data to the US Food and Drug Administration [FDA] as we continue working together to address the evolving challenges of this pandemic,” he said.

    Pfizer and BioNTech have submitted phase 1 data—part of their phase 1/2/3 clinical trial program—evaluating the safety, tolerability, and immunogenicity of a third dose of the Covid-19 vaccine in adult participants from the United States from the phase 1 trial of the two-dose series, the statement said.

    Participants received a 30-ug booster dose of BNT162b2 about nine months after receiving the second dose. Results from this participant group show that the third dose elicited significantly higher neutralizing antibodies against the initial SARS-CoV-2 virus (wild-type) compared to the levels observed after the two-dose primary series and against the Beta variant and the highly infectious Delta variant.

    “We continuously strive to stay at least one step ahead of the virus,” said Ugur Sahin, managing director and co-founder of BioNTech.

    “This is why we aim to expand access to our vaccine for people around the world and are working on various approaches as part of our comprehensive strategy to address the virus and its variants today as well as in the future.”

    Sahin suggested that if the initial data is to be trusted, a third dose of the vaccine could preserve—at the least—and even exceed the already high existing protection levels against the “wild-type virus and relevant variants.” 

    “A booster vaccine could help reduce infection and disease rates in people who have previously been vaccinated and better control the spread of virus variants during the coming season.” 

    The companies are expecting phase III results of the evaluation of the third dose soon, which will be submitted to the US FDA, the European Medicines Agency, and other regulatory authorities worldwide. 

    In the United States, Pfizer and BioNTech plan to seek licensure of the third dose via a supplemental Biologics License Application in individuals 16 years of age and older, pending US FDA approval of the primary application submitted in May 2021.

    A third dose of the Pfizer-BioNTech vaccine is not currently authorized for broad use in the States. However, under the current amended Emergency Use Authorization, it has been authorized on Aug. 12 for administration to individuals aged 12 and above who have undergone solid organ transplantation or who are diagnosed with conditions that are considered to have an equivalent “level of immunocompromise,” as per the statement.

    This authorization is based on information from an independent report evaluating the safety and effectiveness of a third dose in people who received solid organ transplants, the statement said.

    (With inputs from ANI)

    Edited by Amrita Das and Krishna Kakani



    The post Pfizer, BioNTech Expecting Phase III Trial Results For Booster Dose appeared first on Zenger News.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    zenger.news
    • Website

    Related Posts

    TN Doctors Warn About Cuts to TennCare and SNAP Programs

    June 21, 2025

    Pancake and Waffle Mix Recall Updated to ‘Deadly’ Risk by FDA

    June 11, 2025

    Transforming Whole-Person Healthcare: Nashville General Hospital’s Success Story

    January 21, 2025

    Cancer and African Americans

    December 19, 2024

    Preventing and Detecting Type 2 Diabetes Early: A Lifesaving Approach

    December 5, 2024

    Hidden Heroes: Nurses Voted as Tennessee’s Most Valued Workers

    November 26, 2024

    Comments are closed.

    Advertisement
    Business

    Charlotte Knight Griffin Takes Office as TBA President-Elect

    June 30, 2025

    EXCLUSIVE OP-ED: President Joe Biden Commemorating Juneteenth

    June 19, 2025

    FUNdraising Good Times Report from Neighborhoods USA Conference in Jacksonville

    June 4, 2025
    1 2 3 … 384 Next
    Education
    Featured

    TSU Gospel Choir’s award-winning National Performance Now Streaming

    By adminJuly 13, 2025

    Tennessee State University’s award-winning New Direction Gospel Choir earned top honors in the inaugural Best…

    Fisk University Welcomes Antonio Barrino to Lead Band Program and Expand Music Education

    July 7, 2025

    Austin Peay’s MPH program receives $27K for childhood literacy initiative. Community LIFT Project to be implemented at Head Start centers this fall

    June 30, 2025

    TSU, State, reach agreement to reallocate $96M to school

    June 26, 2025
    The Tennessee Tribune
    Facebook X (Twitter) Instagram
    • About Us
    • Digital Subscription
    • Store
    • Advertise With Us
    • Contact
    © 2025 The Tennessee Tribune - Site Designed by No Regret Media.

    Type above and press Enter to search. Press Esc to cancel.

    Our Spring Sale Has Started

    You can see how this popup was set up in our step-by-step guide: https://wppopupmaker.com/guides/auto-opening-announcement-popups/